Sean Donahue
Concepts (537)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vision Screening | 37 | 2025 | 46 | 10.460 |
Why?
| | Amblyopia | 42 | 2025 | 54 | 9.470 |
Why?
| | Oculomotor Muscles | 29 | 2024 | 74 | 9.190 |
Why?
| | Ophthalmologic Surgical Procedures | 23 | 2024 | 82 | 6.610 |
Why?
| | Strabismus | 27 | 2024 | 61 | 5.920 |
Why?
| | Exotropia | 15 | 2023 | 20 | 5.350 |
Why?
| | Esotropia | 13 | 2023 | 25 | 4.620 |
Why?
| | Refractive Errors | 14 | 2022 | 33 | 3.330 |
Why?
| | Visual Acuity | 44 | 2025 | 428 | 3.180 |
Why?
| | Posture | 6 | 2022 | 192 | 2.490 |
Why?
| | Head | 5 | 2022 | 115 | 2.490 |
Why?
| | Ophthalmology | 11 | 2025 | 104 | 2.300 |
Why?
| | Hyperopia | 12 | 2022 | 17 | 2.290 |
Why?
| | Retinopathy of Prematurity | 7 | 2023 | 156 | 2.120 |
Why?
| | Anisometropia | 14 | 2022 | 16 | 2.110 |
Why?
| | Visual Field Tests | 13 | 2024 | 32 | 2.100 |
Why?
| | Vision Disorders | 12 | 2019 | 157 | 2.090 |
Why?
| | Nystagmus, Pathologic | 3 | 2022 | 16 | 2.020 |
Why?
| | Vision, Binocular | 17 | 2024 | 41 | 1.870 |
Why?
| | Child, Preschool | 75 | 2023 | 11158 | 1.870 |
Why?
| | Infant | 56 | 2023 | 9574 | 1.620 |
Why?
| | Visual Fields | 17 | 2024 | 115 | 1.610 |
Why?
| | Eye Abnormalities | 3 | 2019 | 17 | 1.570 |
Why?
| | Ocular Motility Disorders | 6 | 2022 | 32 | 1.490 |
Why?
| | Endophthalmitis | 12 | 2021 | 43 | 1.400 |
Why?
| | Eye Movements | 11 | 2021 | 82 | 1.370 |
Why?
| | Eyeglasses | 12 | 2014 | 22 | 1.340 |
Why?
| | Advisory Committees | 4 | 2018 | 218 | 1.320 |
Why?
| | Child | 70 | 2025 | 21921 | 1.320 |
Why?
| | Diplopia | 6 | 2024 | 26 | 1.300 |
Why?
| | Head Movements | 4 | 2020 | 24 | 1.280 |
Why?
| | Nystagmus, Congenital | 2 | 2020 | 2 | 1.280 |
Why?
| | Eye Infections, Fungal | 7 | 2021 | 20 | 1.280 |
Why?
| | Humans | 180 | 2025 | 138651 | 1.210 |
Why?
| | Myopia | 5 | 2021 | 55 | 1.170 |
Why?
| | Follow-Up Studies | 28 | 2023 | 5112 | 1.130 |
Why?
| | Astigmatism | 6 | 2021 | 17 | 1.080 |
Why?
| | Virtual Reality | 3 | 2024 | 65 | 1.060 |
Why?
| | Referral and Consultation | 10 | 2020 | 793 | 1.040 |
Why?
| | Predictive Value of Tests | 19 | 2022 | 2030 | 0.990 |
Why?
| | Tenotomy | 3 | 2019 | 18 | 0.970 |
Why?
| | Retrospective Studies | 35 | 2024 | 15909 | 0.920 |
Why?
| | Photography | 6 | 2008 | 108 | 0.900 |
Why?
| | Preventive Health Services | 3 | 2018 | 152 | 0.890 |
Why?
| | Treatment Outcome | 33 | 2025 | 10923 | 0.870 |
Why?
| | Papilledema | 3 | 2021 | 42 | 0.870 |
Why?
| | Trochlear Nerve Diseases | 2 | 2023 | 9 | 0.870 |
Why?
| | False Positive Reactions | 12 | 2021 | 124 | 0.870 |
Why?
| | Fungemia | 5 | 2011 | 9 | 0.840 |
Why?
| | Sensitivity and Specificity | 13 | 2023 | 1941 | 0.830 |
Why?
| | Tendons | 3 | 2014 | 123 | 0.830 |
Why?
| | Abnormalities, Multiple | 3 | 2016 | 196 | 0.820 |
Why?
| | Basal Cell Nevus Syndrome | 2 | 2014 | 7 | 0.790 |
Why?
| | Diagnostic Techniques, Ophthalmological | 4 | 2015 | 50 | 0.770 |
Why?
| | Male | 75 | 2024 | 68260 | 0.750 |
Why?
| | Optic Disk | 2 | 2021 | 52 | 0.730 |
Why?
| | Infant, Newborn, Diseases | 1 | 2023 | 113 | 0.730 |
Why?
| | Candidiasis | 5 | 2019 | 63 | 0.720 |
Why?
| | Atropine | 6 | 2011 | 36 | 0.700 |
Why?
| | Lens Implantation, Intraocular | 3 | 2008 | 67 | 0.700 |
Why?
| | Risk Factors | 20 | 2023 | 10252 | 0.690 |
Why?
| | Female | 66 | 2024 | 73763 | 0.640 |
Why?
| | Glaucoma Drainage Implants | 1 | 2020 | 45 | 0.630 |
Why?
| | Trabeculectomy | 1 | 2020 | 74 | 0.620 |
Why?
| | Eye Diseases | 2 | 2020 | 90 | 0.600 |
Why?
| | Eyelids | 1 | 2019 | 42 | 0.600 |
Why?
| | Remote Consultation | 1 | 2020 | 58 | 0.600 |
Why?
| | Adolescent | 29 | 2024 | 21564 | 0.590 |
Why?
| | Prevalence | 13 | 2025 | 2727 | 0.580 |
Why?
| | Hemianopsia | 2 | 2008 | 11 | 0.570 |
Why?
| | Fixation, Ocular | 5 | 2020 | 26 | 0.570 |
Why?
| | Duane Retraction Syndrome | 1 | 2017 | 1 | 0.560 |
Why?
| | Chorioretinitis | 4 | 2011 | 8 | 0.550 |
Why?
| | Bandages | 3 | 2016 | 42 | 0.550 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 194 | 0.540 |
Why?
| | Charities | 2 | 2008 | 12 | 0.540 |
Why?
| | Retina | 4 | 2016 | 305 | 0.530 |
Why?
| | Tonic Pupil | 1 | 2016 | 1 | 0.520 |
Why?
| | Glaucoma | 5 | 2021 | 241 | 0.520 |
Why?
| | Sleep Apnea, Central | 1 | 2016 | 11 | 0.520 |
Why?
| | Hypoventilation | 1 | 2016 | 13 | 0.510 |
Why?
| | Mydriatics | 6 | 2011 | 9 | 0.510 |
Why?
| | Practice Guidelines as Topic | 6 | 2021 | 1567 | 0.510 |
Why?
| | Kidney Diseases, Cystic | 1 | 2016 | 25 | 0.510 |
Why?
| | Ophthalmic Solutions | 3 | 2015 | 78 | 0.500 |
Why?
| | Technology Assessment, Biomedical | 2 | 2016 | 40 | 0.500 |
Why?
| | Infant, Newborn | 13 | 2023 | 6144 | 0.490 |
Why?
| | Retinal Neoplasms | 2 | 2013 | 36 | 0.490 |
Why?
| | Retinoblastoma | 2 | 2013 | 40 | 0.490 |
Why?
| | Depth Perception | 4 | 2017 | 4 | 0.480 |
Why?
| | Ophthalmoplegia | 4 | 2001 | 13 | 0.480 |
Why?
| | Refraction, Ocular | 3 | 2011 | 43 | 0.470 |
Why?
| | Hirschsprung Disease | 1 | 2016 | 89 | 0.470 |
Why?
| | Prescriptions | 2 | 2007 | 73 | 0.470 |
Why?
| | Eye Neoplasms | 1 | 2015 | 28 | 0.460 |
Why?
| | Uveitis, Anterior | 1 | 2015 | 19 | 0.460 |
Why?
| | Sensory Deprivation | 7 | 2011 | 15 | 0.460 |
Why?
| | Lens, Crystalline | 2 | 2008 | 132 | 0.450 |
Why?
| | Mass Screening | 3 | 2020 | 1292 | 0.450 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 26 | 0.450 |
Why?
| | Conjunctiva | 1 | 2015 | 53 | 0.450 |
Why?
| | Cerebellum | 1 | 2016 | 218 | 0.440 |
Why?
| | Optic Nerve Diseases | 5 | 2021 | 47 | 0.440 |
Why?
| | Pseudophakia | 1 | 2014 | 16 | 0.440 |
Why?
| | Reproducibility of Results | 10 | 2024 | 3307 | 0.430 |
Why?
| | Tensile Strength | 1 | 2014 | 96 | 0.430 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 79 | 0.420 |
Why?
| | Adult | 34 | 2024 | 38201 | 0.410 |
Why?
| | Evoked Potentials, Visual | 1 | 2013 | 39 | 0.410 |
Why?
| | Gestational Age | 5 | 2023 | 916 | 0.410 |
Why?
| | Optic Atrophy, Hereditary, Leber | 2 | 2023 | 7 | 0.400 |
Why?
| | Eye Infections, Bacterial | 5 | 1998 | 39 | 0.390 |
Why?
| | Telemedicine | 2 | 2020 | 873 | 0.390 |
Why?
| | Down Syndrome | 1 | 2019 | 484 | 0.380 |
Why?
| | Botulinum Toxins | 1 | 2013 | 44 | 0.380 |
Why?
| | Stress, Mechanical | 1 | 2014 | 487 | 0.370 |
Why?
| | Angiogenesis Inhibitors | 2 | 2010 | 230 | 0.360 |
Why?
| | Age Factors | 8 | 2021 | 3256 | 0.360 |
Why?
| | Chin | 2 | 2022 | 7 | 0.350 |
Why?
| | Magnetic Resonance Imaging | 10 | 2019 | 3637 | 0.350 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2011 | 87 | 0.340 |
Why?
| | Pediatrics | 2 | 2016 | 1078 | 0.340 |
Why?
| | Cataract | 2 | 2023 | 221 | 0.340 |
Why?
| | Leukemic Infiltration | 2 | 2015 | 7 | 0.330 |
Why?
| | Reoperation | 4 | 2020 | 579 | 0.330 |
Why?
| | Candidemia | 2 | 2021 | 14 | 0.330 |
Why?
| | Vestibular Nuclei | 1 | 2010 | 7 | 0.330 |
Why?
| | Oculomotor Nerve Diseases | 2 | 2021 | 13 | 0.320 |
Why?
| | Optic Neuritis | 4 | 1999 | 46 | 0.320 |
Why?
| | Intraocular Pressure | 3 | 2021 | 313 | 0.320 |
Why?
| | Central Venous Pressure | 1 | 2009 | 15 | 0.320 |
Why?
| | Wet Macular Degeneration | 1 | 2010 | 57 | 0.310 |
Why?
| | Zellweger Syndrome | 1 | 2009 | 2 | 0.310 |
Why?
| | Jugular Veins | 1 | 2009 | 42 | 0.310 |
Why?
| | Artifacts | 2 | 2021 | 130 | 0.310 |
Why?
| | Vitamin A Deficiency | 1 | 2009 | 27 | 0.300 |
Why?
| | Anterior Chamber | 2 | 2008 | 26 | 0.300 |
Why?
| | Incidence | 8 | 2021 | 2747 | 0.300 |
Why?
| | Corneal Ulcer | 1 | 2009 | 21 | 0.300 |
Why?
| | Infant, Premature | 2 | 2023 | 578 | 0.300 |
Why?
| | Postoperative Complications | 6 | 2010 | 2722 | 0.300 |
Why?
| | Prospective Studies | 18 | 2024 | 7554 | 0.300 |
Why?
| | Observation | 3 | 2016 | 56 | 0.300 |
Why?
| | Accommodation, Ocular | 2 | 2020 | 14 | 0.290 |
Why?
| | Tennessee | 6 | 2008 | 50 | 0.290 |
Why?
| | Phakic Intraocular Lenses | 1 | 2008 | 1 | 0.290 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2008 | 47 | 0.280 |
Why?
| | Neural Pathways | 1 | 2010 | 303 | 0.280 |
Why?
| | Optometry | 2 | 2006 | 9 | 0.280 |
Why?
| | Internationality | 1 | 2008 | 158 | 0.270 |
Why?
| | Cellulitis | 2 | 1998 | 55 | 0.270 |
Why?
| | Blindness, Cortical | 1 | 2007 | 6 | 0.270 |
Why?
| | Tomography, Optical Coherence | 3 | 2021 | 234 | 0.260 |
Why?
| | Acrocephalosyndactylia | 1 | 2007 | 12 | 0.260 |
Why?
| | Fovea Centralis | 4 | 2010 | 15 | 0.260 |
Why?
| | Antibodies, Monoclonal | 2 | 2010 | 1436 | 0.250 |
Why?
| | Pupil | 4 | 2000 | 22 | 0.250 |
Why?
| | Face | 1 | 2007 | 173 | 0.250 |
Why?
| | Oculomotor Nerve | 2 | 2021 | 7 | 0.240 |
Why?
| | Middle Aged | 17 | 2024 | 33604 | 0.240 |
Why?
| | Foundations | 1 | 2006 | 29 | 0.240 |
Why?
| | Eye Protective Devices | 2 | 2016 | 8 | 0.240 |
Why?
| | Diabetes Insipidus | 1 | 2005 | 6 | 0.240 |
Why?
| | Photorefractive Keratectomy | 1 | 2006 | 20 | 0.240 |
Why?
| | Septo-Optic Dysplasia | 1 | 2005 | 5 | 0.240 |
Why?
| | Visual Pathways | 3 | 2001 | 59 | 0.230 |
Why?
| | Opportunistic Infections | 1 | 2005 | 45 | 0.230 |
Why?
| | Vitreous Body | 5 | 2010 | 121 | 0.230 |
Why?
| | Marfan Syndrome | 1 | 2005 | 43 | 0.230 |
Why?
| | Reflex, Vestibulo-Ocular | 2 | 2001 | 12 | 0.230 |
Why?
| | Practice Patterns, Physicians' | 2 | 2004 | 1323 | 0.220 |
Why?
| | Brain Concussion | 2 | 2022 | 579 | 0.220 |
Why?
| | Diagnosis, Differential | 7 | 2019 | 1482 | 0.220 |
Why?
| | Age Distribution | 4 | 2011 | 393 | 0.220 |
Why?
| | Cornea | 1 | 2006 | 150 | 0.220 |
Why?
| | Exophthalmos | 1 | 2004 | 19 | 0.210 |
Why?
| | Leukemia, Myeloid | 1 | 2004 | 47 | 0.210 |
Why?
| | Muscles | 3 | 1991 | 332 | 0.210 |
Why?
| | Aphakia, Postcataract | 1 | 2003 | 4 | 0.210 |
Why?
| | Contact Lenses | 1 | 2003 | 10 | 0.210 |
Why?
| | Medical Records | 2 | 2007 | 180 | 0.210 |
Why?
| | Nerve Fibers | 2 | 2021 | 100 | 0.210 |
Why?
| | Graves Ophthalmopathy | 1 | 2024 | 13 | 0.210 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2024 | 815 | 0.210 |
Why?
| | Retinoscopy | 2 | 2016 | 3 | 0.210 |
Why?
| | Tomography, X-Ray Computed | 8 | 2014 | 2698 | 0.210 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2023 | 70 | 0.210 |
Why?
| | Tonometry, Ocular | 2 | 2021 | 102 | 0.210 |
Why?
| | United States | 10 | 2025 | 14938 | 0.210 |
Why?
| | Xanthomatosis, Cerebrotendinous | 1 | 2023 | 5 | 0.210 |
Why?
| | Iris | 2 | 2005 | 22 | 0.200 |
Why?
| | Pseudotumor Cerebri | 2 | 2000 | 30 | 0.200 |
Why?
| | Combined Modality Therapy | 4 | 2013 | 1235 | 0.200 |
Why?
| | Hematoma, Subdural | 2 | 2000 | 20 | 0.200 |
Why?
| | Retinal Hemorrhage | 2 | 2000 | 22 | 0.200 |
Why?
| | Birth Weight | 2 | 2023 | 508 | 0.200 |
Why?
| | Parvovirinae | 1 | 2022 | 5 | 0.200 |
Why?
| | Young Adult | 6 | 2023 | 13305 | 0.200 |
Why?
| | Aging | 3 | 2011 | 1855 | 0.200 |
Why?
| | Paralysis | 1 | 2023 | 70 | 0.200 |
Why?
| | Ophthalmologists | 1 | 2022 | 13 | 0.180 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 2 | 2019 | 260 | 0.180 |
Why?
| | Eye Diseases, Hereditary | 1 | 2021 | 13 | 0.180 |
Why?
| | Neonatal Screening | 1 | 2023 | 167 | 0.180 |
Why?
| | Receptors, Angiotensin | 1 | 2001 | 11 | 0.180 |
Why?
| | Physicians' Offices | 2 | 2016 | 19 | 0.180 |
Why?
| | Pandemics | 2 | 2020 | 1641 | 0.180 |
Why?
| | Vitrectomy | 3 | 2005 | 77 | 0.180 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2001 | 55 | 0.180 |
Why?
| | Intubation | 2 | 2014 | 6 | 0.180 |
Why?
| | Optic Neuropathy, Ischemic | 1 | 2001 | 31 | 0.180 |
Why?
| | Dacryocystorhinostomy | 2 | 2014 | 12 | 0.180 |
Why?
| | Pilot Projects | 5 | 2021 | 1765 | 0.170 |
Why?
| | Nasolacrimal Duct | 2 | 2014 | 10 | 0.170 |
Why?
| | Academies and Institutes | 1 | 2021 | 55 | 0.170 |
Why?
| | Daucus carota | 1 | 2000 | 2 | 0.170 |
Why?
| | Aphakia | 1 | 2000 | 2 | 0.170 |
Why?
| | Sports Medicine | 1 | 2022 | 113 | 0.170 |
Why?
| | Retinal Ganglion Cells | 1 | 2021 | 113 | 0.170 |
Why?
| | Postoperative Period | 2 | 2020 | 355 | 0.170 |
Why?
| | Masks | 1 | 2021 | 66 | 0.160 |
Why?
| | Battered Child Syndrome | 1 | 2000 | 7 | 0.160 |
Why?
| | United Arab Emirates | 1 | 2020 | 7 | 0.160 |
Why?
| | Subarachnoid Hemorrhage, Traumatic | 1 | 1999 | 4 | 0.160 |
Why?
| | Low Tension Glaucoma | 1 | 2019 | 1 | 0.160 |
Why?
| | Videoconferencing | 1 | 2020 | 66 | 0.160 |
Why?
| | Vision, Ocular | 1 | 2000 | 44 | 0.160 |
Why?
| | Horner Syndrome | 2 | 1996 | 6 | 0.160 |
Why?
| | Leukomalacia, Periventricular | 1 | 2019 | 9 | 0.160 |
Why?
| | Sex Distribution | 2 | 2011 | 377 | 0.160 |
Why?
| | Planning Techniques | 1 | 2019 | 17 | 0.160 |
Why?
| | Sports | 1 | 2022 | 217 | 0.160 |
Why?
| | Bacteremia | 2 | 2019 | 214 | 0.160 |
Why?
| | Glaucoma, Open-Angle | 1 | 2021 | 104 | 0.160 |
Why?
| | Societies, Medical | 3 | 2025 | 839 | 0.150 |
Why?
| | Physical Examination | 2 | 2019 | 238 | 0.150 |
Why?
| | Syndrome | 1 | 2020 | 377 | 0.150 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2022 | 236 | 0.150 |
Why?
| | Eye Infections, Viral | 1 | 1998 | 9 | 0.150 |
Why?
| | Temporal Lobe | 1 | 1999 | 102 | 0.150 |
Why?
| | Electroretinography | 1 | 1998 | 50 | 0.150 |
Why?
| | Retinal Rod Photoreceptor Cells | 1 | 1998 | 18 | 0.150 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 1998 | 21 | 0.150 |
Why?
| | Aged | 8 | 2024 | 24024 | 0.150 |
Why?
| | Polymorphism, Genetic | 1 | 2001 | 623 | 0.140 |
Why?
| | Costs and Cost Analysis | 1 | 2019 | 222 | 0.140 |
Why?
| | Eyelid Diseases | 1 | 1998 | 22 | 0.140 |
Why?
| | Orbital Diseases | 1 | 1998 | 34 | 0.140 |
Why?
| | Haemophilus Infections | 1 | 1998 | 41 | 0.140 |
Why?
| | Motion Perception | 1 | 1998 | 18 | 0.140 |
Why?
| | Pupil Disorders | 1 | 1997 | 7 | 0.140 |
Why?
| | Neuromuscular Junction | 2 | 1988 | 63 | 0.140 |
Why?
| | Staphylococcal Infections | 2 | 2022 | 387 | 0.140 |
Why?
| | Fatal Outcome | 2 | 2015 | 309 | 0.140 |
Why?
| | Intracranial Hypertension | 1 | 1998 | 42 | 0.140 |
Why?
| | Retinal Diseases | 1 | 1998 | 96 | 0.140 |
Why?
| | Craniocerebral Trauma | 1 | 1999 | 170 | 0.140 |
Why?
| | Hydrocephalus | 2 | 2010 | 108 | 0.130 |
Why?
| | Spleen | 1 | 2019 | 523 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2010 | 549 | 0.130 |
Why?
| | Chronic Disease | 1 | 2023 | 1805 | 0.130 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 896 | 0.130 |
Why?
| | Quality of Life | 5 | 2022 | 2954 | 0.130 |
Why?
| | p-Hydroxyamphetamine | 1 | 1996 | 1 | 0.130 |
Why?
| | Synapses | 3 | 1991 | 426 | 0.130 |
Why?
| | Conjunctivitis, Viral | 1 | 1996 | 3 | 0.130 |
Why?
| | International Classification of Diseases | 1 | 2018 | 138 | 0.130 |
Why?
| | Keratitis | 1 | 1996 | 18 | 0.130 |
Why?
| | Conjunctivitis, Bacterial | 1 | 1996 | 13 | 0.130 |
Why?
| | Sarcopenia | 1 | 2018 | 81 | 0.130 |
Why?
| | Severity of Illness Index | 5 | 2019 | 2851 | 0.120 |
Why?
| | Wounds, Nonpenetrating | 1 | 1999 | 304 | 0.120 |
Why?
| | Volunteers | 2 | 2010 | 37 | 0.120 |
Why?
| | Respiration, Artificial | 1 | 2021 | 670 | 0.120 |
Why?
| | Eye Foreign Bodies | 2 | 1994 | 26 | 0.120 |
Why?
| | Sensory Thresholds | 4 | 1999 | 31 | 0.120 |
Why?
| | Retinal Detachment | 2 | 1997 | 74 | 0.120 |
Why?
| | Proteomics | 1 | 2023 | 1110 | 0.120 |
Why?
| | Piperazines | 1 | 1998 | 345 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 1034 | 0.120 |
Why?
| | Aged, 80 and over | 3 | 2020 | 7677 | 0.120 |
Why?
| | Athletic Injuries | 1 | 2022 | 517 | 0.120 |
Why?
| | Prognosis | 4 | 2015 | 3984 | 0.120 |
Why?
| | Vitamin A | 2 | 2009 | 57 | 0.120 |
Why?
| | Prosthesis Implantation | 1 | 1997 | 156 | 0.120 |
Why?
| | Biopsy, Needle | 2 | 2011 | 187 | 0.120 |
Why?
| | Myelinolysis, Central Pontine | 1 | 1995 | 3 | 0.120 |
Why?
| | Functional Laterality | 2 | 2011 | 232 | 0.120 |
Why?
| | Weight Loss | 1 | 2000 | 783 | 0.110 |
Why?
| | Epilepsy | 1 | 1999 | 335 | 0.110 |
Why?
| | Anti-Bacterial Agents | 2 | 1996 | 1818 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 1998 | 847 | 0.110 |
Why?
| | Recurrence | 3 | 2011 | 1084 | 0.110 |
Why?
| | Orthoptics | 1 | 2014 | 1 | 0.110 |
Why?
| | Parents | 1 | 2003 | 1421 | 0.110 |
Why?
| | Antifungal Agents | 2 | 2011 | 143 | 0.110 |
Why?
| | Retinal Neovascularization | 1 | 1994 | 28 | 0.110 |
Why?
| | Developmental Disabilities | 1 | 2016 | 268 | 0.100 |
Why?
| | Polycystic Kidney Diseases | 1 | 2014 | 73 | 0.100 |
Why?
| | Cephalosporins | 1 | 1994 | 45 | 0.100 |
Why?
| | Infusions, Intra-Arterial | 1 | 2013 | 61 | 0.100 |
Why?
| | Cryotherapy | 1 | 2013 | 20 | 0.100 |
Why?
| | Algorithms | 1 | 2001 | 1740 | 0.100 |
Why?
| | Vancomycin | 1 | 1994 | 82 | 0.100 |
Why?
| | Anti-Dyskinesia Agents | 1 | 2013 | 8 | 0.100 |
Why?
| | Facial Paralysis | 1 | 1993 | 24 | 0.100 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 1993 | 59 | 0.100 |
Why?
| | Bevacizumab | 2 | 2010 | 139 | 0.100 |
Why?
| | Interferon-alpha | 1 | 1994 | 195 | 0.100 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 1993 | 71 | 0.100 |
Why?
| | Acute Disease | 4 | 2004 | 994 | 0.100 |
Why?
| | Conjunctival Diseases | 1 | 1992 | 21 | 0.100 |
Why?
| | Silicone Oils | 1 | 1992 | 29 | 0.100 |
Why?
| | Brain | 2 | 2001 | 2792 | 0.100 |
Why?
| | Translocation, Genetic | 1 | 1993 | 108 | 0.100 |
Why?
| | Injections, Intramuscular | 1 | 2013 | 130 | 0.090 |
Why?
| | Brain Ischemia | 1 | 1996 | 343 | 0.090 |
Why?
| | Dependovirus | 2 | 2023 | 75 | 0.090 |
Why?
| | Hyperthermia, Induced | 1 | 2013 | 120 | 0.090 |
Why?
| | Macular Degeneration | 1 | 1994 | 166 | 0.090 |
Why?
| | Glucocorticoids | 2 | 2015 | 528 | 0.090 |
Why?
| | Recovery of Function | 2 | 2010 | 665 | 0.090 |
Why?
| | Sarcoidosis | 1 | 1993 | 158 | 0.090 |
Why?
| | Administration, Oral | 2 | 2009 | 788 | 0.090 |
Why?
| | Ranibizumab | 1 | 2010 | 21 | 0.080 |
Why?
| | Genetic Therapy | 2 | 2023 | 314 | 0.080 |
Why?
| | Health Records, Personal | 1 | 2010 | 28 | 0.080 |
Why?
| | Los Angeles | 1 | 2010 | 74 | 0.080 |
Why?
| | Remission, Spontaneous | 1 | 2010 | 40 | 0.080 |
Why?
| | Seizures | 2 | 2007 | 431 | 0.080 |
Why?
| | Saccule and Utricle | 1 | 2010 | 7 | 0.080 |
Why?
| | Patient Care Management | 1 | 2010 | 56 | 0.080 |
Why?
| | TRPP Cation Channels | 1 | 2010 | 81 | 0.080 |
Why?
| | Orbit | 1 | 2010 | 71 | 0.080 |
Why?
| | Torsion Abnormality | 1 | 2010 | 19 | 0.080 |
Why?
| | Disease Progression | 3 | 2010 | 2749 | 0.080 |
Why?
| | Semicircular Canals | 1 | 2010 | 24 | 0.080 |
Why?
| | Injections | 1 | 2010 | 189 | 0.080 |
Why?
| | Cysts | 1 | 2010 | 114 | 0.080 |
Why?
| | Formamides | 1 | 1989 | 7 | 0.080 |
Why?
| | User-Computer Interface | 1 | 2010 | 164 | 0.080 |
Why?
| | Infratentorial Neoplasms | 1 | 2010 | 64 | 0.080 |
Why?
| | Hospitals, Veterans | 1 | 2010 | 255 | 0.080 |
Why?
| | Candida | 2 | 2019 | 41 | 0.070 |
Why?
| | Research Design | 2 | 2018 | 1118 | 0.070 |
Why?
| | Electrophysiology | 1 | 1989 | 217 | 0.070 |
Why?
| | Reflex, Pupillary | 2 | 1999 | 6 | 0.070 |
Why?
| | Hong Kong | 1 | 2008 | 8 | 0.070 |
Why?
| | Ultrasonography | 2 | 2010 | 745 | 0.070 |
Why?
| | Intermediate Filament Proteins | 1 | 1988 | 58 | 0.070 |
Why?
| | Mutation, Missense | 1 | 2010 | 334 | 0.070 |
Why?
| | Blood Pressure Determination | 1 | 2009 | 143 | 0.070 |
Why?
| | Observer Variation | 1 | 2009 | 350 | 0.070 |
Why?
| | Spinal Dysraphism | 1 | 2010 | 95 | 0.070 |
Why?
| | Brazil | 1 | 2008 | 166 | 0.070 |
Why?
| | Reference Standards | 1 | 2008 | 184 | 0.070 |
Why?
| | Vitamins | 1 | 2009 | 183 | 0.070 |
Why?
| | Emergency Service, Hospital | 1 | 2019 | 2116 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2011 | 1518 | 0.070 |
Why?
| | Hypoxia, Brain | 1 | 2007 | 9 | 0.070 |
Why?
| | Preoperative Care | 1 | 2010 | 367 | 0.070 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2007 | 17 | 0.060 |
Why?
| | Eye Injuries | 2 | 2000 | 53 | 0.060 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2007 | 42 | 0.060 |
Why?
| | Disease Management | 1 | 2010 | 622 | 0.060 |
Why?
| | Muscle Contraction | 1 | 1989 | 431 | 0.060 |
Why?
| | International Agencies | 1 | 2006 | 33 | 0.060 |
Why?
| | Treatment Failure | 1 | 2007 | 351 | 0.060 |
Why?
| | Jaundice, Neonatal | 1 | 2005 | 8 | 0.060 |
Why?
| | Lasers, Excimer | 1 | 2006 | 29 | 0.060 |
Why?
| | Alaska | 1 | 2006 | 85 | 0.060 |
Why?
| | Hypopituitarism | 1 | 2005 | 16 | 0.060 |
Why?
| | Double-Blind Method | 1 | 2010 | 1949 | 0.060 |
Why?
| | Eye Injuries, Penetrating | 1 | 2005 | 20 | 0.060 |
Why?
| | Central Nervous System | 1 | 2007 | 263 | 0.060 |
Why?
| | Rats, Inbred F344 | 3 | 1991 | 267 | 0.060 |
Why?
| | Reference Values | 3 | 2007 | 799 | 0.060 |
Why?
| | Legislation, Medical | 1 | 2004 | 11 | 0.050 |
Why?
| | Kidney Failure, Chronic | 1 | 2010 | 586 | 0.050 |
Why?
| | Urinary Tract Infections | 1 | 2007 | 193 | 0.050 |
Why?
| | Voluntary Health Agencies | 1 | 2004 | 6 | 0.050 |
Why?
| | Blood Glucose | 2 | 2008 | 2239 | 0.050 |
Why?
| | Treatment Refusal | 1 | 2005 | 96 | 0.050 |
Why?
| | Withholding Treatment | 1 | 2004 | 77 | 0.050 |
Why?
| | Time Factors | 3 | 2010 | 6851 | 0.050 |
Why?
| | Cholestanol | 1 | 2023 | 4 | 0.050 |
Why?
| | HIV Infections | 1 | 1998 | 2941 | 0.050 |
Why?
| | Premature Birth | 1 | 2007 | 335 | 0.050 |
Why?
| | Decompression, Surgical | 1 | 2024 | 112 | 0.050 |
Why?
| | Random Allocation | 1 | 2003 | 363 | 0.050 |
Why?
| | Animals | 6 | 2014 | 37217 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2844 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2005 | 556 | 0.050 |
Why?
| | Kidney | 1 | 2010 | 1466 | 0.050 |
Why?
| | Scotoma | 2 | 1999 | 7 | 0.050 |
Why?
| | Guideline Adherence | 1 | 2007 | 559 | 0.050 |
Why?
| | Blindness | 1 | 2002 | 48 | 0.050 |
Why?
| | Saccades | 1 | 2022 | 42 | 0.050 |
Why?
| | Bile Acids and Salts | 1 | 2023 | 151 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2152 | 0.050 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 2001 | 8 | 0.050 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2001 | 23 | 0.050 |
Why?
| | Inflammation | 2 | 2023 | 2850 | 0.050 |
Why?
| | DNA, Mitochondrial | 1 | 2023 | 208 | 0.040 |
Why?
| | Patient Compliance | 1 | 2006 | 598 | 0.040 |
Why?
| | Genetic Vectors | 1 | 2022 | 336 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2005 | 460 | 0.040 |
Why?
| | Rats | 4 | 1991 | 5594 | 0.040 |
Why?
| | Vitreous Hemorrhage | 1 | 2000 | 9 | 0.040 |
Why?
| | Geniculate Bodies | 1 | 2019 | 20 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2001 | 5520 | 0.040 |
Why?
| | Microbiological Techniques | 3 | 1995 | 33 | 0.040 |
Why?
| | Data Interpretation, Statistical | 1 | 2001 | 364 | 0.040 |
Why?
| | Pulmonary Ventilation | 1 | 2000 | 84 | 0.040 |
Why?
| | Microbial Sensitivity Tests | 2 | 2007 | 351 | 0.040 |
Why?
| | Siblings | 1 | 2020 | 216 | 0.040 |
Why?
| | Muscle Development | 2 | 1991 | 114 | 0.040 |
Why?
| | Automation | 1 | 1999 | 99 | 0.040 |
Why?
| | Visual Cortex | 1 | 2019 | 74 | 0.040 |
Why?
| | Streptococcal Infections | 2 | 1998 | 148 | 0.040 |
Why?
| | Blood Sedimentation | 1 | 1998 | 40 | 0.040 |
Why?
| | Transplant Recipients | 1 | 2020 | 173 | 0.040 |
Why?
| | Haemophilus Vaccines | 1 | 1998 | 30 | 0.040 |
Why?
| | Optic Nerve | 1 | 1998 | 66 | 0.040 |
Why?
| | Bacteria | 3 | 1995 | 867 | 0.040 |
Why?
| | Organ Size | 1 | 2019 | 471 | 0.040 |
Why?
| | Streptococcus | 1 | 1998 | 29 | 0.040 |
Why?
| | Sildenafil Citrate | 1 | 1998 | 59 | 0.040 |
Why?
| | Brain Neoplasms | 1 | 2007 | 1267 | 0.040 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 1998 | 22 | 0.040 |
Why?
| | Haemophilus influenzae | 1 | 1998 | 63 | 0.040 |
Why?
| | Probability | 1 | 1999 | 308 | 0.040 |
Why?
| | CD4 Lymphocyte Count | 1 | 1998 | 280 | 0.040 |
Why?
| | Sulfones | 1 | 1998 | 110 | 0.030 |
Why?
| | Postoperative Care | 1 | 2019 | 274 | 0.030 |
Why?
| | Animals, Newborn | 2 | 1991 | 859 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2000 | 1229 | 0.030 |
Why?
| | Purines | 1 | 1998 | 179 | 0.030 |
Why?
| | HIV | 1 | 1998 | 246 | 0.030 |
Why?
| | Molluscum Contagiosum | 1 | 1996 | 4 | 0.030 |
Why?
| | False Negative Reactions | 1 | 1996 | 60 | 0.030 |
Why?
| | Trachoma | 1 | 1996 | 2 | 0.030 |
Why?
| | Corneal Diseases | 1 | 1997 | 44 | 0.030 |
Why?
| | Photic Stimulation | 1 | 1997 | 252 | 0.030 |
Why?
| | Electroencephalography | 1 | 1999 | 444 | 0.030 |
Why?
| | Viral Load | 1 | 1998 | 495 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2018 | 227 | 0.030 |
Why?
| | Neutropenia | 1 | 1997 | 157 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 1996 | 49 | 0.030 |
Why?
| | Inpatients | 1 | 2020 | 502 | 0.030 |
Why?
| | Brain Edema | 1 | 1996 | 64 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1656 | 0.030 |
Why?
| | Health Status | 1 | 2021 | 819 | 0.030 |
Why?
| | Carotid Artery, Internal | 1 | 1995 | 44 | 0.030 |
Why?
| | Carotid Artery Diseases | 1 | 1995 | 61 | 0.030 |
Why?
| | Fractures, Bone | 1 | 2000 | 397 | 0.030 |
Why?
| | Multiple Sclerosis | 1 | 2000 | 460 | 0.030 |
Why?
| | Brain Injuries | 1 | 2000 | 501 | 0.030 |
Why?
| | Equipment Contamination | 1 | 1995 | 71 | 0.030 |
Why?
| | Fundus Oculi | 1 | 1994 | 74 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1317 | 0.030 |
Why?
| | Child Abuse | 1 | 2020 | 542 | 0.030 |
Why?
| | Ceftazidime | 1 | 1994 | 6 | 0.030 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2014 | 8 | 0.030 |
Why?
| | Anesthesia, Local | 1 | 2014 | 24 | 0.030 |
Why?
| | Aminoglycosides | 1 | 1994 | 25 | 0.030 |
Why?
| | Corneal Injuries | 1 | 1994 | 46 | 0.030 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2014 | 73 | 0.030 |
Why?
| | Karyotyping | 1 | 1993 | 103 | 0.020 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 5803 | 0.020 |
Why?
| | Emulsions | 1 | 1992 | 55 | 0.020 |
Why?
| | Foreign-Body Reaction | 1 | 1992 | 32 | 0.020 |
Why?
| | Prednisone | 1 | 1993 | 227 | 0.020 |
Why?
| | Eye Enucleation | 1 | 2011 | 15 | 0.020 |
Why?
| | Mutation | 1 | 2023 | 3987 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 1993 | 502 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2019 | 3523 | 0.020 |
Why?
| | Muscle, Skeletal | 1 | 2001 | 1729 | 0.020 |
Why?
| | Primary Health Care | 1 | 2022 | 1777 | 0.020 |
Why?
| | Muscle Denervation | 1 | 1991 | 9 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 3139 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1994 | 1352 | 0.020 |
Why?
| | RNA Splice Sites | 1 | 2010 | 49 | 0.020 |
Why?
| | Injections, Intraocular | 1 | 2010 | 13 | 0.020 |
Why?
| | Multicenter Studies as Topic | 1 | 2011 | 320 | 0.020 |
Why?
| | Tubocurarine | 1 | 1989 | 6 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2010 | 398 | 0.020 |
Why?
| | Exons | 1 | 2010 | 353 | 0.020 |
Why?
| | Fixatives | 1 | 1988 | 14 | 0.020 |
Why?
| | RNA Splicing | 1 | 2010 | 270 | 0.020 |
Why?
| | Neurofilament Proteins | 1 | 1988 | 51 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 327 | 0.020 |
Why?
| | Ganglia, Spinal | 1 | 1988 | 85 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 4092 | 0.020 |
Why?
| | Selection Bias | 1 | 2007 | 39 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 1988 | 385 | 0.020 |
Why?
| | Reflex | 1 | 1987 | 70 | 0.020 |
Why?
| | Obesity | 1 | 2000 | 2962 | 0.020 |
Why?
| | Hindlimb | 1 | 1987 | 133 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1731 | 0.020 |
Why?
| | Lung | 1 | 2020 | 4106 | 0.020 |
Why?
| | Axons | 1 | 1988 | 195 | 0.020 |
Why?
| | Attitude to Health | 1 | 2010 | 457 | 0.020 |
Why?
| | Lung Diseases | 1 | 1993 | 785 | 0.020 |
Why?
| | Motor Neurons | 1 | 1988 | 229 | 0.020 |
Why?
| | Body Weight | 1 | 1991 | 992 | 0.020 |
Why?
| | Phosphoproteins | 1 | 1988 | 338 | 0.020 |
Why?
| | Spinal Cord | 1 | 1988 | 373 | 0.020 |
Why?
| | Action Potentials | 1 | 1989 | 485 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2923 | 0.020 |
Why?
| | Internet | 1 | 2010 | 669 | 0.010 |
Why?
| | Electromyography | 1 | 1987 | 401 | 0.010 |
Why?
| | Korea | 1 | 2005 | 17 | 0.010 |
Why?
| | Video Games | 1 | 2005 | 28 | 0.010 |
Why?
| | Odds Ratio | 1 | 2007 | 1044 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 768 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2006 | 272 | 0.010 |
Why?
| | Sympathectomy, Chemical | 1 | 2004 | 5 | 0.010 |
Why?
| | Patient Selection | 1 | 2007 | 676 | 0.010 |
Why?
| | Reading | 1 | 2005 | 136 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 2006 | 608 | 0.010 |
Why?
| | Risk Assessment | 1 | 2011 | 3433 | 0.010 |
Why?
| | Neurologic Examination | 1 | 2000 | 128 | 0.010 |
Why?
| | Cerebrospinal Fluid Pressure | 1 | 1999 | 3 | 0.010 |
Why?
| | Acetazolamide | 1 | 1999 | 24 | 0.010 |
Why?
| | Spinal Puncture | 1 | 1999 | 20 | 0.010 |
Why?
| | Ventriculoperitoneal Shunt | 1 | 1999 | 37 | 0.010 |
Why?
| | Intracranial Pressure | 1 | 1999 | 60 | 0.010 |
Why?
| | Reaction Time | 1 | 1999 | 421 | 0.010 |
Why?
| | Cohort Studies | 1 | 2007 | 5697 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 1999 | 1032 | 0.010 |
Why?
| | Facial Pain | 1 | 1995 | 13 | 0.010 |
Why?
| | Isotonic Solutions | 1 | 1995 | 38 | 0.010 |
Why?
| | Evaluation Studies as Topic | 1 | 1995 | 175 | 0.010 |
Why?
| | Survival Rate | 1 | 1999 | 1935 | 0.010 |
Why?
| | Magnetic Resonance Angiography | 1 | 1995 | 243 | 0.010 |
Why?
| | Radiography | 1 | 1995 | 841 | 0.010 |
Why?
|
|
Donahue's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|